Paul Hudson, CEO of Sanofi (NASDAQ: SNY), stated this week that the France-based pharmaceutical company has no plans to develop a competing product in the GLP-1 drug market, dominated by Novo Nordisk (CPH: NOVO-B) and Eli Lilly (NYSE: LLY), despite significant demand. However, Houman Ashrafian, head of R&D, indicated that Sanofi is exploring opportunities in the weight-management sector through next-generation therapies that promise greater specificity and reduced side effects.
Ashrafian noted that the discovery phase may leverage genetic signals associated with metabolism, potentially leading to treatments designed for underweight or frail patients.- Flcube.com
